STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] PERRIGO Co plc Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Perrigo Company plc (PRGO) furnished an 8-K announcing two items: it released earnings for the third quarter ended September 27, 2025 (Item 2.02), and it is initiating a strategic review of its infant formula business (Item 7.01). Both related press releases were furnished as Exhibits 99.1 and 99.2 on November 5, 2025.

The company highlighted use of non-GAAP measures to evaluate ongoing operating trends, comparability, and performance assessment. For recent periods, adjustments included amortization of acquired intangibles, unusual litigation, restructuring and termination benefits, impairment charges, infant formula remediation, divestiture gains or losses, foreign currency translation, non-GAAP tax adjustments, and other items. Management also references constant currency net sales and free cash flow among the metrics it reviews.

The earnings and strategic review press releases are expressly furnished, not filed, limiting their incorporation by reference under the Exchange Act and Securities Act.

Positive
  • None.
Negative
  • None.

Insights

PRGO furnished Q3 results and began an infant formula review.

Perrigo reported Q3 results for the period ended September 27, 2025, with details presented via a furnished press release. The company emphasizes non-GAAP metrics that exclude amortization, litigation, restructuring, impairments, divestiture gains/losses, FX translation, and tax adjustments to present underlying operating trends.

The company also announced a strategic review of its infant formula business on November 5, 2025. A review can encompass alternatives such as retention, partnership, or potential transactions, but the excerpt does not specify outcomes or timing.

Because both communications are furnished (Items 2.02 and 7.01), they are not deemed filed. Actual impact depends on subsequent disclosures detailing performance and any decisions resulting from the review.

0001585364false00015853642025-11-052025-11-050001585364prgo:OrdinaryShares0001ParValueMember2025-11-052025-11-050001585364prgo:A4.900SeniorNotesDueJune152030Member2025-11-052025-11-050001585364prgo:A6.125SeniorNotesDue2032Member2025-11-052025-11-050001585364prgo:A5.375SeniorNotesDue2032Member2025-11-052025-11-050001585364prgo:A5.30UnsecuredSeniorNotesDueNovember152043Member2025-11-052025-11-050001585364prgo:A49SeniorLoanDue2024Member2025-11-052025-11-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________
 FORM 8-K
______________________________________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
November 5, 2025
______________________________________________
Perrigo Company plc

(Exact name of registrant as specified in its charter)
_______________________________________________

Commission file number 001-36353
Ireland Not Applicable
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)

The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74
+353 1 7094000

(Address, including zip code, and telephone number, including
area code, of registrant’s principal executive offices)

Not Applicable
(Former name or former address, if changed since last report)
________________________________________ 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
    (17 CFR 240.14d-2(b))
        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
        (17 CFR 240.13e-4(c))

Securities Registered pursuant to section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Ordinary shares, €0.001 par valuePRGONew York Stock Exchange
4.900% Notes due 2030
PRGO30New York Stock Exchange
6.125% Notes due 2032
PRGO32A
New York Stock Exchange
5.375% Notes due 2032
PRGO32B
New York Stock Exchange
5.300% Notes due 2043PRGO43New York Stock Exchange
4.900% Notes due 2044PRGO44New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


ITEM 2.02.    Results of Operations and Financial Condition

On November 5, 2025, Perrigo Company plc (the “Company”) released earnings for the third quarter ended September 27, 2025. The press release related to the Company’s earnings is attached as Exhibit 99.1.

The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and, where applicable, with companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as amortization expense, unusual litigation, impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The intangible asset amortization excluded from these non-GAAP financial measures represents the entire amount recorded within the Company’s GAAP financial statements and is excluded because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. The revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. The non-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management’s view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation.

Non-GAAP measures related to profit measurements, which may include adjusted net income, adjusted gross profit, adjusted operating income, adjusted diluted earnings per share, adjusted gross margin, adjusted operating margin, organic gross profit, organic operating income, organic operating margin, organic diluted earnings per share, free cash flow, and constant currency net sales, are useful to investors as they provide them with supplemental information to enhance their understanding of the Company’s underlying business performance and trends, and enhance the ability of investors and analysts to compare the Company’s period-to-period financial results. Management believes that adjusted gross margin and adjusted operating margin are useful to investors, in addition to the reasons discussed above, by allowing them to more easily compare and analyze trends in the Company’s peer business group and assisting them in comparing the Company’s overall performance to that of its competitors. The Company also discloses net sales growth excluding the impact of currency on an organic basis. The Company believes these supplemental financial measures provide investors with consistency in financial reporting, enabling meaningful comparisons of past and present underlying operating results, and also facilitate analysis of the Company’s operating performance and acquisition and divestiture trends.

Investors should consider the non-GAAP measures provided in the attached earnings release in conjunction with, and not in lieu of, the Company's reported financial statements in accordance with GAAP.
    
In deriving some or all of the non-GAAP measures provided, reported results for the periods below were adjusted for the following items:

Three Months Ended September 27, 2025 Results

Amortization expense related primarily to acquired intangible assets
Unusual litigation
Restructuring charges and other termination benefits
Gain on divestitures
Other non-GAAP adjustments
Non-GAAP tax adjustments
Foreign currency translation movement

Three Months Ended September 28, 2024 Results

Amortization expense related primarily to acquired intangible assets
Unusual litigation
Restructuring charges and other termination benefits
Impairment charges
Infant formula remediation
Loss on early debt extinguishment
Gain on divestitures and brand sales
Other non-GAAP adjustments
Non-GAAP tax adjustments
Foreign currency translation movement

Nine Months Ended September 27, 2025 Results

Amortization expense related primarily to acquired intangible assets
Restructuring charges and other termination benefits
Unusual litigation
Impairment charges
Loss on divestitures
Infant formula remediation
Other non-GAAP adjustments
Non-GAAP tax adjustments
Foreign currency translation movement

Nine Months Ended September 28, 2024 Results

Amortization expense related primarily to acquired intangible assets
Restructuring charges and other termination benefits
Unusual litigation
Impairment charges
Infant formula remediation
Acquisition and integration-related charges and contingent consideration adjustments
Loss on early debt extinguishment
Gain on divestitures and brand sales
Other non-GAAP adjustments
Non-GAAP tax adjustments
Foreign currency translation movement

The information in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), except as shall be expressly set forth by specific reference in such filing.

ITEM 7.01.    Regulation FD Disclosure

On November 5, 2025, the Company issued a press release announcing that it is initiating a strategic review of its infant formula business, a copy of which is furnished as Exhibit 99.2 and is incorporated herein by reference. The information contained in this paragraph, as well as Exhibit 99.2 referenced herein, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section. The information contained in this paragraph, as well as Exhibit 99.2 referenced herein, shall not be deemed incorporated by reference into any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing.



ITEM 9.01.    Financial Statements and Exhibits

(d)Exhibits
Exhibit NumberDescription
99.1
Press Release issued by Perrigo Company plc on November 5, 2025 furnished solely pursuant to Item 2.02 of Form 8-K.
99.2
Press Release issued by Perrigo Company plc on November 5, 2025 furnished solely pursuant to Item 7.01 of Form 8-K.
104Cover Page Interactive Data file (embedded within the Inline XBRL document).



SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



(Registrant)
PERRIGO COMPANY PLC
By:/s/ Eduardo Bezerra
Dated: November 5, 2025Eduardo Bezerra
Chief Financial Officer

FAQ

What did Perrigo (PRGO) announce in this 8-K?

Perrigo furnished its Q3 results for the quarter ended September 27, 2025, and announced a strategic review of its infant formula business.

Which exhibits were included with Perrigo’s 8-K (PRGO)?

Exhibit 99.1 is the Q3 earnings press release; Exhibit 99.2 is the press release announcing the infant formula strategic review.

Are the Perrigo (PRGO) disclosures considered filed or furnished?

They are furnished, not filed, and therefore are not subject to Section 18 liability nor automatically incorporated by reference.

What non-GAAP adjustments does Perrigo (PRGO) reference?

Items include amortization of acquired intangibles, unusual litigation, restructuring, impairments, divestiture gains/losses, foreign currency translation, and non-GAAP tax adjustments.

What period does Perrigo’s Q3 2025 cover?

The quarter ended on September 27, 2025, with the related press release furnished on November 5, 2025.

What is Perrigo (PRGO) reviewing in its strategic review?

The company is initiating a strategic review of its infant formula business; outcomes are not specified in the excerpt.
Perrigo Co Plc

NYSE:PRGO

PRGO Rankings

PRGO Latest News

PRGO Latest SEC Filings

PRGO Stock Data

2.78B
136.97M
0.41%
105.88%
5.38%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2